Market revenue in 2023 | USD 6.9 million |
Market revenue in 2030 | USD 12.4 million |
Growth rate | 8.7% (CAGR from 2023 to 2030) |
Largest segment | Kits & reagents |
Fastest growing segment | Services |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Instruments, Kits & Reagents, Services |
Key market players worldwide | Thermo Fisher Scientific Inc, Lonza Group Ltd, Merck KGaA, Charles River Laboratories International Inc, Asahi Kasei Corp, Sartorius AG, Eurofins Scientific SE, PromoCell GmbH, ATCC, InvivoGen |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to mycoplasma testing market will help companies and investors design strategic landscapes.
Kits & reagents was the largest segment with a revenue share of 53.62% in 2023. Horizon Databook has segmented the Saudi Arabia mycoplasma testing market based on instruments, kits & reagents, services covering the revenue growth of each sub-segment from 2018 to 2030.
The growth of Saudi Arabia mycoplasma testing market can primarily be attributed to the various initiatives being undertaken by the government to expand biotechnology sector in the country. Organizations like the King Abdullah University of Science and Technology (KAUST) facilitate biotechnology R&D activities in Saudi Arabia. Key players are expanding in the country to capitalize on the increasing demand for cell biology-related products.
For instance, in November 2022, Sysmex opened its subsidiary in Saudi Arabia to cater to customers in the country. Furthermore, in January 2024, Qiagen expanded its business in Saudi Arabia by opening a headquarters in Riyadh. The company decided to expand in the region due to the increasing demand for infectious disease control. With increasing need for testing, mycoplasma testing services are also likely to be in demand due to QC protocols.
Furthermore, increasing private & public partnerships is further anticipated to boost the demand for cell culture products in Saudi Arabia. For instance, in October 2019, Saudi Arabian Investment Authority (SAGIA) signed an MOU with Korea’s GL Rapha Co. to manufacture biological drugs worth USD 320 million in the country. Key players in the country include Thermo Fisher Scientific, Merck KGaA, and others.
Horizon Databook provides a detailed overview of country-level data and insights on the Saudi Arabia mycoplasma testing market , including forecasts for subscribers. This country databook contains high-level insights into Saudi Arabia mycoplasma testing market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account